奥扎格雷钠联合降栓酶用于脑血栓治疗的有效性

Effectiveness of Sodium Ozagrel Combined with Antithrombotic Enzyme in Treatment of Cerebral Thrombosis

目的研究脑血栓患者运用降栓酶和奥扎格雷钠联合治疗的临床有效性和安全性。方法选取2015年3月—2016年4月期间德州市第二人民医院收治的90例脑血栓患者,利用随机数字法将其平均分成观察组和对照组,每组45例,常规对照组仅使用奥扎格雷钠开药物治疗,观察组则是在对照组治疗基础上加用降栓酶药物联合治疗。对两组患者用药前后的神经功能缺损程度(NIHSS)评分变化;记录两组患者治疗有效性和安全性。结果观察组患者治疗总有效率为91.11%、不良反应发生率17.78%,均优于对照组的64.44%、42.22%,数据对比差异有统计学意义(P<0.05);治疗前两组患者的NIHSS评分差异无统计学意义,治疗后观察组患者NIHSS评分为(15.63±8.16)分优于对照组的(19.65±8.80)分,组间数据差异有统计学意义(P<0.05)。结论临床上针对脑血栓患者运用降栓酶以及奥扎格雷钠联合治疗,其临床效果显著,具有较高的临床推广价值。

Objective To research the effectiveness and safety of sodium ozagrel combined with antithrombotic enzyme in treatment of cerebral thrombosis. Methods 90 cases of patients with cerebral thrombosis admitted and treated in our hospital from March 2015 to April 2016 were selected and randomly divided into two groups with h45 cases in each,the control group adopted the sodium ozagrel drugs, while the observation group adopted the sodium ozagrel combined with antithrombotic enzyme, and the NIHSS score changes before and after medication were compared between the two groups and the effectiveness and safety of the two groups were recorded. Results The total effective rate and incidence rate of adverse reactions in the observation group were better than those in the control group(91.11%, 17.78% vs64.44%, 42.22%), and the differences were statistically significant(P <0.05), before treatment, the difference in the NIHSS score between the two groups was obvious, and the NIHSS score in the observation group after treatment was better than that in the control group [(15.63±8.16)points vs(19.65±8.80)points], and the difference was statistically significant(P<0.05). Conclusion The clinical effect of sodium ozagrel combined with antithrombotic enzyme in treatment of cerebral thrombosis is obvious, which is of higher clinical promotion value.